NCT05802264View on ClinicalTrials.gov

Study to Assess Amphotericin B Cystetic for Inhalation (ABCI) Doses in Healthy Volunteers & People with Cystic Fibrosis

PHASE1RecruitingINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

March 21, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Cystic Fibrosis
Interventions
COMBINATION_PRODUCT

ABCI

Subjects will receive ABCI via oral inhalation

COMBINATION_PRODUCT

Placebo

Subjects will receive ABCI via oral inhalation

Trial Locations (5)

2145

RECRUITING

Westmead Hospital, Westmead

2605

RECRUITING

Canberra Hospital, Canberra

3168

RECRUITING

Monash Medical Centre, Clayton

4032

RECRUITING

The Prince Charles Hospital, Brisbane

Unknown

RECRUITING

New Zealand Clinical Research, Christchurch

Sponsors

Collaborators (1)

DevPro Biopharma
All Listed Sponsors
collaborator

DevPro Biopharma

INDUSTRY

lead

Cystetic Medicines, Inc.

INDUSTRY

NCT05802264 - Study to Assess Amphotericin B Cystetic for Inhalation (ABCI) Doses in Healthy Volunteers & People with Cystic Fibrosis | Biotech Hunter | Biotech Hunter